September 21, 2015

NovoCure Limited Announces Launch of Initial Public Offering

September 21, 2015 07:00 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–NovoCure Limited, a commercial stage oncology company pioneering a novel therapy for solid tumors, announced today the launch of its initial public offering of 12,500,000 shares of its common… Read More
learn more
September 21, 2015

NovoCure Limited Announces Launch of Initial Public Offering

September 21, 2015 07:00 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–NovoCure Limited, a commercial stage oncology company pioneering a novel therapy for solid tumors, announced today the launch of its initial public offering of 12,500,000 shares of its common… Read More
learn more
September 21, 2015

NovoCure Limited Announces Launch of Initial Public Offering

September 21, 2015 07:00 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–NovoCure Limited, a commercial stage oncology company pioneering a novel therapy for solid tumors, announced today the launch of its initial public offering of 12,500,000 shares of its common… Read More
learn more
September 9, 2015

Novocure to Present the Latest Data from the EF-14 Clinical Trial in Newly Diagnosed GBM at the 15th Interim Meeting of the World Federation of Neurosurgical Societies

September 09, 2015 07:00 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure, a commercial stage oncology company, announced today that the latest data from the EF-14 randomized phase 3 trial of Tumor Treating Fields (TTFields) in newly diagnosed glioblastoma (GBM)… Read More
learn more
September 9, 2015

Novocure to Present the Latest Data from the EF-14 Clinical Trial in Newly Diagnosed GBM at the 15th Interim Meeting of the World Federation of Neurosurgical Societies

September 09, 2015 07:00 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure, a commercial stage oncology company, announced today that the latest data from the EF-14 randomized phase 3 trial of Tumor Treating Fields (TTFields) in newly diagnosed glioblastoma (GBM)… Read More
learn more
September 9, 2015

Novocure to Present the Latest Data from the EF-14 Clinical Trial in Newly Diagnosed GBM at the 15th Interim Meeting of the World Federation of Neurosurgical Societies

September 09, 2015 07:00 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure, a commercial stage oncology company, announced today that the latest data from the EF-14 randomized phase 3 trial of Tumor Treating Fields (TTFields) in newly diagnosed glioblastoma (GBM)… Read More
learn more
September 8, 2015

Novocure Announces Optune Now Available at more than 200 Leading Cancer Centers across the United States

Optune, a Tumor Treating Fields delivery system, provides a novel, non-invasive treatment for recurrent glioblastoma, the most common and deadly malignant primary brain cancer Optune, a Tumor Treating Fields delivery system, provides a novel, non-invasive treatment for recurrent glioblastoma, the most common and deadly malignant primary brain… Read More
learn more
September 8, 2015

Novocure Announces Optune Now Available at more than 200 Leading Cancer Centers across the United States

Optune, a Tumor Treating Fields delivery system, provides a novel, non-invasive treatment for recurrent glioblastoma, the most common and deadly malignant primary brain cancer Optune, a Tumor Treating Fields delivery system, provides a novel, non-invasive treatment for recurrent glioblastoma, the most common and deadly malignant primary brain… Read More
learn more
September 8, 2015

Novocure Announces Optune Now Available at more than 200 Leading Cancer Centers across the United States

Optune, a Tumor Treating Fields delivery system, provides a novel, non-invasive treatment for recurrent glioblastoma, the most common and deadly malignant primary brain cancer Optune, a Tumor Treating Fields delivery system, provides a novel, non-invasive treatment for recurrent glioblastoma, the most common and deadly malignant primary brain… Read More
learn more
September 4, 2015

Novocure to Present Clinical Trial Designs and Preclinical Data on Tumor Treating Fields at the 16th World Conference on Lung Cancer

September 04, 2015 10:24 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure, a commercial stage oncology company, announced today that its ongoing and future clinical trial designs in lung cancer will be presented at the 16th World Conference on Lung… Read More
learn more